Navigation Links
Medivation Announces Fourth Quarter and Year-End 2008 Teleconference and Webcast on March 16, 2009
Date:3/9/2009

SAN FRANCISCO, March 9 /PRNewswire-FirstCall/ -- Medivation, Inc. (Nasdaq: MDVN) today announced that it will host a teleconference and webcast with management to discuss fourth quarter and year-end 2008 financial results and provide a general business update on Monday, March 16, 2009, at 4:30 p.m. Eastern Time. A press release for the fourth quarter and year ended December 31, 2008 will be released after markets close on March 16, 2009.

Interested parties may call 877-718-5104 from the U.S. or +1-719-325-4794 internationally. Individuals interested in listening to the live call via webcast may do so by visiting http://www.medivation.com. A replay of the webcast will be available on the Company's website for 30 days.

About Medivation

Medivation, Inc. is a biopharmaceutical company focused on the rapid development of novel small molecule drugs to treat serious diseases for which there are limited treatment options. Medivation aims to transform the treatment of these diseases and offer hope to critically ill patients and their caregivers. In September 2008, Medivation announced a global agreement with Pfizer Inc to develop and commercialize Dimebon for the treatment of Alzheimer's and Huntington's diseases. With Pfizer, the Company is conducting a broad Dimebon clinical development program, including a pivotal and confirmatory Phase 3 trial, known as the CONNECTION study, in patients with mild-to-moderate Alzheimer's disease. The program also includes additional trials planned to begin this year in Alzheimer's disease, as well as further development of Dimebon in patients with mild-to-moderate Huntington's disease. In addition, a Phase 1-2 clinical trial of MDV3100 in patients with castration-resistant (also known as hormone-refractory) prostate cancer is ongoing. For more information, please visit us at http://www.medivation.com.


'/>"/>
SOURCE Medivation, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Medivation to Host Conference Call and Slide Presentation at 4:30 p.m. EST Wednesday, February 25, to Discuss New MDV3100 Efficacy and Safety Data From Trial in Castration-Resistant Prostate Cancer Patients
2. Medivation Announces Participation in Upcoming Conferences
3. Medivation Announces Participation in 27th Annual J.P. Morgan Healthcare Conference
4. Medivation Announces Participation in Upcoming Conferences
5. Medivation to Present at Cowen and Companys 28th Annual Health Care Conference
6. Medivation Plans to Initiate Pivotal Confirmatory Phase 3 Trial of Dimebon(TM) for Alzheimers Disease in Second Quarter of 2008
7. Medivation to Announce Early Positive Data from Phase 1-2 Hormone Refractory Prostate Cancer Trial and Host Conference Call and Webcast on Monday, November 5, 2007
8. National Western Life Announces 2008 Fourth Quarter and 2008 Earnings
9. Celebrity Chef Cat Cora Announces First Pregnancy
10. National Patient Advocate Foundation Announces 2009 Elections of Health Policy Leaders to Executive Board of Directors
11. CEL-SCI Announces Exclusive Licensing Agreement for Cancer Drug Multikine(R) for Republic of South Africa
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/24/2017)... ... ... The results from the American Cancer Society’s newest report on ... patients: incidents of cancer is down as is the likelihood of prostate cancer patients ... dropped from its peak of 215.1 in 1991 to 161.2 in 2014 (per 100K ...
(Date:1/24/2017)... ... 24, 2017 , ... American Family Care (AFC) has opened a new 4,000+ ... for residents in the area. The Bedford clinic will be the nineteenth location opened ... by Dave Adams and Dr. Kristina Orio. Adams and Orio also independently own and ...
(Date:1/24/2017)... ... January 24, 2017 , ... TopConsumerReviews.com recently gave a ... premenstrual syndrome, or PMS . , Most women of child-bearing age will experience ... constipation, irritability, headaches, fatigue, and other discomfort. For some women, the effects ...
(Date:1/24/2017)... ... January 24, 2017 , ... “Who Would Have Dreamed: A Novel of Miracles”: a beautiful ... tried to understand its purpose in her life. “Who Would Have Dreamed: A Novel of ... and a love of writing. , Sharon shares that she started her spiritual ...
(Date:1/24/2017)... ... 24, 2017 , ... “The Octagon of Spiritual Balances”: a guide for ... the creation of published author, Pastor Bernard J. Weathers, pastor of Word of Faith ... in religious education and a master degree in theology. , ““The Octagon of Spiritual ...
Breaking Medicine News(10 mins):
(Date:1/24/2017)... Jan. 24, 2017   Keneric Healthcare , ... cost effective patient care products, today announced their ... expand the reach of both companies by leveraging ... expertise. Angelini Pharma Inc ... now include Keneric Healthcare,s RTD™ Wound Dressing (antibacterial/antifungal). ...
(Date:1/24/2017)... FRANCISCO , January 24, 2017 The global  ... USD 239.8 billion by 2025, based on a new report by Grand ... cancer is projected to drive the market over the forecast period. Advancements ... are also estimated to boost growth.  Continue ... ...
(Date:1/24/2017)... , Jan. 23, 2017 Optoelectronic ... and control light. The interaction of these components ... in a wide range of applications. These components ... and defense, telecommunications, and healthcare among others. ... owing to its low power consumption, reliability, scalability, ...
Breaking Medicine Technology: